tela bio, inc., a surgical reconstruction company, was created out of the desire to do things differently. combining the drive and innovation of a start-up with a seasoned medical technology team, the company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. based in malvern, pennsylvania, this science-driven company is collaborating with leading surgeons to reinvigorate the soft tissue reconstruction market and bring cost-effective solutions to hospitals, surgeons and patients. please see our social media community guidelines at http://bit.ly/1uvcx0l
Company profile
Ticker
TELA
Exchange
Website
CEO
Antony Koblish
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
TELA Bio, Limited ...
IRS number
455320061
TELA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
8-K
Other Events
15 Apr 24
S-8
Registration of securities for employees
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
21 Mar 24
8-K
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
20 Mar 24
EFFECT
Notice of effectiveness
21 Nov 23
CORRESP
Correspondence with SEC
16 Nov 23
Transcripts
TELA
Earnings call transcript
2023 Q4
21 Mar 24
TELA
Earnings call transcript
2023 Q3
9 Nov 23
TELA
Earnings call transcript
2023 Q2
9 Aug 23
TELA
Earnings call transcript
2023 Q1
11 May 23
TELA
Earnings call transcript
2022 Q4
21 Mar 23
TELA
Earnings call transcript
2022 Q3
9 Nov 22
TELA
Earnings call transcript
2022 Q2
11 Aug 22
TELA
Earnings call transcript
2022 Q1
14 May 22
TELA
Earnings call transcript
2021 Q4
22 Mar 22
TELA
Earnings call transcript
2021 Q3
13 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 58.20 mm | 58.20 mm | 58.20 mm | 58.20 mm | 58.20 mm | 58.20 mm |
Cash burn (monthly) | 2.35 mm | (no burn) | 3.39 mm | 3.44 mm | 2.32 mm | 3.40 mm |
Cash used (since last report) | 16.23 mm | n/a | 23.39 mm | 23.69 mm | 16.01 mm | 23.43 mm |
Cash remaining | 41.97 mm | n/a | 34.81 mm | 34.51 mm | 42.19 mm | 34.77 mm |
Runway (months of cash) | 17.8 | n/a | 10.3 | 10.0 | 18.2 | 10.2 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 25 |
Closed positions | 10 |
Increased positions | 23 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 220.15 bn |
Total shares | 27.64 mm |
Total puts | 400.00 |
Total calls | 6.90 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Essex Woodlands Management | 4.11 mm | $41.64 bn |
Ew Healthcare Partners Fund 2 | 4.11 mm | $34.20 mm |
Orbimed Advisors | 2.84 mm | $28.72 bn |
First Light Asset Management | 1.73 mm | $17.48 bn |
AIGH Capital Management | 1.66 mm | $16.79 bn |
Opaleye Management | 1.58 mm | $16.01 bn |
Hirschman Orin | 1.52 mm | $13.89 mm |
BLK Blackrock | 1.01 mm | $10.25 bn |
Pentwater Capital Management | 878.80 k | $8.90 bn |
Vanguard | 868.52 k | $8.80 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Gregory A. Firestone | Common Stock | Payment of exercise | Dispose F | No | No | 5.67 | 119 | 674.73 | 50,627 |
31 Mar 24 | Antony Koblish | Common Stock | Payment of exercise | Dispose F | No | No | 5.67 | 385 | 2.18 k | 370,009 |
31 Mar 24 | Paul Talmo | Common Stock | Payment of exercise | Dispose F | No | No | 5.67 | 190 | 1.08 k | 68,860 |
31 Mar 24 | Megan Smeykal | Common Stock | Payment of exercise | Dispose F | No | No | 5.67 | 96 | 544.32 | 29,000 |
31 Mar 24 | Peter C. Murphy | Common Stock | Payment of exercise | Dispose F | No | No | 5.67 | 163 | 924.21 | 48,129 |
News
JMP Securities Reiterates Market Outperform on TELA Bio, Maintains $15 Price Target
22 Mar 24
Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $12
22 Mar 24
Recap: TELA Bio Q4 Earnings
21 Mar 24
TELA Bio Q4 2023 GAAP EPS $(0.53) Misses $(0.44) Estimate, Sales $16.998M Beat $16.392M Estimate
21 Mar 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Press releases
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
15 Apr 24
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
8 Apr 24
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
21 Mar 24
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 Feb 24